Company Information

Location

Frenchs Forest , NSW, Australia

CEO

Gary Phillips

Website

www.pharmaxis.com.au

Social

LinkedIn

Arix Representative

The Company’s product pipeline is founded on its expertise in the chemistry of amine oxidase inhibitors and includes Semicarbazide-Sensitive Amine Oxidase (SSAO) for Non- Alcoholic Steatohepatitis (NASH) and diabetic retinopathy; Lysyl Oxidase Like Inhibitors (LOXL2) targeting fibrotic diseases including NASH, pulmonary fibrosis, kidney fibrosis and cardiac fibrosis; Lysyl Oxidase Inhibitors (LOX) targeting severe fibrotic indications including scarring and some cancers; and a dual SSAO/MPO inhibitor for respiratory inflammation, cardiovascular inflammation and inflammatory bowel diseases.

Pharmaxis’ acknowledged expertise in amine oxide inhibitors has attracted interest from leading pharmaceutical companies looking to partner in this rapidly expanding area of medical need.